Document is current
Any future updates will be listed below
-
Authors
Karjula, Topias
Elomaa, Hanna
Väyrynen, Sara A.
Kuopio, Teijo
Ahtiainen, Maarit
Mustonen, Olli
Puro, Iiris
Niskakangas, Anne
Mecklin, Jukka-Pekka
Böhm, Jan
Wirta, Erkki-Ville
Seppälä, Toni T.
Sihvo, Eero
Yannopoulos, Fredrik
Helminen, Olli
Väyrynen, Juha P.
-
Funding
Funding for this research was provided by:
Finnish State Research Funding
Jane ja Aatos Erkon Säätiö
Instrumentariumin Tiedesäätiö
Mary och Georg C. Ehrnrooths Stiftelse
Syöpäsäätiö
Sigrid Juséliuksen Säätiö
University of Oulu
- License Information
-
More Information
Article History
Received: 25 November 2023
Accepted: 29 January 2024
First Online: 22 February 2024
Declarations
:
: T.T.S. declares consultation fee from Amgen Finland. T.T.S is CEO and co-owner of Healthfund Finland and Clinical Advisory board member of LS Cancer Diag. The other authors declare no conflict of interest.
: The Oulu University Hospital Ethics Committee (EETMK 81/2008) approved the study.
: The Finnish National Authority of Medicolegal Affairs (VALVIRA) waived the need for informed consent due to the retrospective nature of the study. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
